Viking Therapeutics (VKTX) Stock: Buy, Sell, or Hold?
VKTX - Viking Therapeutics, Inc
$31.98
-0.15 (-0.47%)
▼
5d:
-5.89%
30d:
-6.0%
90d:
+11.78%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 28, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 4, 2026 at $34.87 · last confirmed Sep 11, 2026
Strength: 9.2/10
Get Alerted When VKTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: VKTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: VKTX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: VKTX is currently trading at $31.98, which is considered oversold relative to its 30-day fair value range of $32.71 to $34.42.
Technical Outlook: Technically, VKTX is in a uptrend. The price is currently testing key support at $31.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VKTX scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $92.39 (+188.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VKTX is in a uptrend. The price is currently testing key support at $31.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VKTX scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $92.39 (+188.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$32.71 -
$34.42
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 188.9% below Wall St target ($92.39)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$32.71 -
$34.42
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$31.70
Resistance Level
$34.95
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.40
Wall Street Target
$92.39
(+188.9%)
Share & Embed Analysis
Last updated: September 12, 2026 10:16 AM ET
Data refreshes hourly during market hours. Next update: 11:16 AM
Data refreshes hourly during market hours. Next update: 11:16 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VKTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$315 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
